TCM Biotech International Corp.
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceutica… Read more
TCM Biotech International Corp. (4169) - Total Liabilities
Latest total liabilities as of September 2025: NT$118.34 Million TWD
Based on the latest financial reports, TCM Biotech International Corp. (4169) has total liabilities worth NT$118.34 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TCM Biotech International Corp. - Total Liabilities Trend (2019–2024)
This chart illustrates how TCM Biotech International Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TCM Biotech International Corp. Competitors by Total Liabilities
The table below lists competitors of TCM Biotech International Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Wufangzhai Industry Co. Ltd. A
SHG:603237
|
China | CN¥1.04 Billion |
|
POSCO M-TECH Co. Ltd
KQ:009520
|
Korea | ₩35.08 Billion |
|
Fluxys Belgium
BR:FLUX
|
Belgium | €2.73 Billion |
|
Zhejiang Kaier New Materials
SHE:300234
|
China | CN¥191.97 Million |
|
Horizon Kinetics Holding Corporation
PINK:HKHC
|
USA | $118.74 Million |
|
Unit Corporation
PINK:UNTC
|
USA | $76.68 Million |
|
Grand Korea Leisure Co. Ltd
KO:114090
|
Korea | ₩204.46 Billion |
|
Refrigeration Electrical Engineering Corp
VN:REE
|
Vietnam | ₫15.28 Trillion |
Liability Composition Analysis (2019–2024)
This chart breaks down TCM Biotech International Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TCM Biotech International Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TCM Biotech International Corp. (2019–2024)
The table below shows the annual total liabilities of TCM Biotech International Corp. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$123.28 Million | -53.98% |
| 2023-12-31 | NT$267.88 Million | -17.88% |
| 2022-12-31 | NT$326.20 Million | +8.07% |
| 2021-12-31 | NT$301.84 Million | +18.36% |
| 2020-12-31 | NT$255.02 Million | +0.31% |
| 2019-12-31 | NT$254.24 Million | -- |